SNY · Nasdaq, OTC · CIK 0001121404

Sanofi

Sanofi’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 26, 2026. Its EDGAR record lists 2 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
EUR 7.9B
Form 4 filings on record, past 12 months
2

Company overview

Legal name (as filed)
Sanofi
Tickers
SNY, SNYNF
SEC Central Index Key (CIK)
0001121404
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
PARIS, France
State or country of incorporation
France
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#164 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Sanofi’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in EUR; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
EUR 6.3BFY2021EUR 8.5BFY2022EUR 5.4BFY2023EUR 5.6BFY2024EUR 7.9BFY2025
SNY annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net incomeEUR 6.3BEUR 8.5BEUR 5.4BEUR 5.6BEUR 7.9B
Diluted EPS—EUR 6.66EUR 4.30EUR 4.43EUR 6.37
Total assetsEUR 120.2BEUR 126.7BEUR 126.5BEUR 132.8BEUR 126.8B
Cash and equivalentsEUR 1.4BEUR 1.4BEUR 1.5BEUR 1.3BEUR 877.0M

XBRL tags used: netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

SNY latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 17, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 26, 20266-KReport of a foreign private issuer· period Oct 26, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Sanofi, by form type:

6-K ×24SCHEDULE 13G/A ×33 ×24 ×213F-HR ×211-K ×2NT 11-K ×2N-PX ×1SD ×1SCHEDULE 13G ×1
SNY recent filings
FiledFormWhat it isOriginal
Oct 26, 20266-KReport of a foreign private issuer· period Oct 26, 2026Document · Index
Oct 26, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Oct 1, 20266-KReport of a foreign private issuer· period Oct 1, 2026Document · Index
Sep 17, 20266-KReport of a foreign private issuer· period Sep 17, 2026Document · Index
Aug 25, 2026N-PXN-PX· period Jun 30, 2026Document · Index
Aug 12, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 10, 2026Document · Index
Aug 12, 20263Initial statement of beneficial ownership· period Aug 6, 2026Document · Index
Aug 7, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 6, 2026Document · Index
Aug 6, 20266-KReport of a foreign private issuer· period Aug 6, 2026Document · Index
Aug 4, 20263Initial statement of beneficial ownership· period Aug 4, 2026Document · Index
Jul 30, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jul 30, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jul 28, 202613F-HRInstitutional investment manager holdings report· period Jun 30, 2026Document · Index
Jul 27, 20266-KReport of a foreign private issuer· period Jul 27, 2026Document · Index
Jul 22, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 17, 20266-KReport of a foreign private issuer· period Jul 17, 2026Document · Index
Jul 7, 20266-KReport of a foreign private issuer· period Jul 7, 2026Document · Index
Jun 30, 202611-KAnnual report of employee stock plans· period Dec 31, 2025Document · Index
Jun 30, 202611-KAnnual report of employee stock plans· period Dec 31, 2025Document · Index
Jun 30, 2026NT 11-KNT 11-K· period Dec 31, 2025Document · Index
Jun 30, 2026NT 11-KNT 11-K· period Dec 31, 2025Document · Index
Jun 24, 20266-KReport of a foreign private issuer· period Jun 24, 2026Document · Index
Jun 22, 20266-KReport of a foreign private issuer· period Jun 22, 2026Document · Index
Jun 12, 20266-KReport of a foreign private issuer· period Jun 12, 2026Document · Index
Jun 8, 20266-KReport of a foreign private issuer· period Jun 8, 2026Document · Index
May 28, 2026SDSpecialized disclosure report (conflict minerals)Document · Index
May 27, 20266-KReport of a foreign private issuer· period May 27, 2026Document · Index
May 7, 202613F-HRInstitutional investment manager holdings report· period Mar 31, 2026Document · Index
May 6, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
May 5, 20266-KReport of a foreign private issuer· period May 5, 2026Document · Index
Apr 29, 20266-KReport of a foreign private issuer· period Apr 29, 2026Document · Index
Apr 27, 20266-KReport of a foreign private issuer· period Apr 27, 2026Document · Index
Apr 23, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Apr 15, 20266-KReport of a foreign private issuer· period Apr 15, 2026Document · Index
Apr 10, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Mar 31, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Mar 24, 20266-KReport of a foreign private issuer· period Mar 24, 2026Document · Index
Mar 10, 20266-KReport of a foreign private issuer· period Mar 10, 2026Document · Index
Mar 4, 20266-KReport of a foreign private issuer· period Mar 4, 2026Document · Index
Mar 3, 20266-KReport of a foreign private issuer· period Mar 3, 2026Document · Index

Insider filing activity

2 Form 4 filings appear in Sanofi’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001121404 and XBRL company facts. Sanofi on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.